8-K: Acura Pharmaceuticals Provides Update on LTX-03 Development Following FDA Meeting

Acura Pharmaceuticals and its partner Abuse Deterrent Pharma, LLC, met with the FDA to discuss the development of LTX-03, a hydrocodone and acetaminophen tablet designed with abuse-deterrent properties.

Summary

• Acura Pharmaceuticals and Abuse Deterrent Pharma, LLC, had a second meeting with the FDA regarding the development of LTX-03.
• LTX-03 utilizes Acura's LIMITx technology, aiming to provide lower peak drug blood concentrations as more tablets are ingested.
• The companies expect to conduct an additional pharmacokinetic study (AP-LTX-310) comparing a single dose of LTX-03 to an FDA Reference Standard drug in fed and fasted states.
• The FDA was amenable to describing the pharmacokinetic characteristics of LTX-03 in the final approved labeling, but advised against a label claim suggesting a lower risk of overdose based solely on pharmacokinetic testing.
• Acura believes a study to support a lower risk safety claim would best be accomplished post-NDA approval, which cannot be assured.
• The FDA indicated that the lower 5/325mg and 7.5/325mg dosage strengths of LTX-03 will require a plan to scientifically support those products in the NDA.
• Acura is evaluating whether to conduct such a study for the NDA submission or to study and add these strengths after NDA approval, which cannot be assured.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is progressing with LTX-03 development, there are still significant regulatory hurdles and uncertainties regarding FDA approval and commercialization.

Positives

• The FDA is amenable to describing the unique pharmacokinetic characteristics of LTX-03 in the final approved labeling.
• The company is moving forward with development of LTX-03.

Negatives

• The FDA advised that a label claim suggesting a lower risk of overdose would not be warranted by pharmacokinetic testing alone.
• The FDA indicated that the lower 5/325mg and 7.5/325mg dosage strengths of LTX-03 will require a plan to scientifically support those products in the NDA.
• There is no guarantee of NDA approval.

Risks

• The company's ability to fund or obtain funding for continuing operations and product development is a risk.
• There is a risk that the FDA may not accept an NDA for LTX-03 by the agreed target date.
• Licensees may terminate the license prior to commercialization.
• Clinical studies may not yield expected results, and product candidates may not receive FDA approval.
• Food or other drugs may adversely impact the safety and/or efficacy of products.
• The company may not be able to get the pharmacokinetic profile or other features of product candidates described in the FDA-approved label.
• Licensing partners may not develop additional products or utilize Acura for such development.
• LIMITx may not retard the release of opioid active ingredients as dose levels increase.
• The company and its licensees may not be able to successfully launch and commercialize products and technologies.
• The company and its licensees may not be able to obtain necessary regulatory approvals and commercialize products utilizing technologies.
• The market may not accept the products, and the timing of commercial launch and competitive environment are uncertain.
• The company may not be able to develop and enter into additional license agreements for product candidates.
• The company may not be able to avoid infringement of patents, trademarks, and other proprietary rights of third parties.
• Patents may not protect products from generic competition, and the company may not be able to protect and enforce patent rights.
• The development program for product candidates may be inadequate, and additional clinical studies may be required.
• Regulatory requirements may change.
• Adverse safety findings may relate to commercialized products or product candidates in development.
• The company may not be able to obtain FDA approval of labeling for product candidates for the proposed indications or promote the features of technologies.
• Product candidates may not ultimately perform as intended in commercial settings.

Future Outlook

The company expects to conduct one additional human pharmacokinetic study of a single tablet dose of LTX-03 compared to a single FDA Reference Standard drug in the fed and fasted state, designated AP-LTX-310, which will commence following production of new clinical supplies of LTX-03. The company is also evaluating whether to conduct a study for the NDA submission or to study and add lower dosage strengths after NDA approval.

Management Comments

• The Company believes a study to support a lower risk safety claim would best be accomplished post-NDA approval, which cannot be assured.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies developing abuse-deterrent opioid formulations. The FDA's feedback on LTX-03 highlights the challenges and regulatory hurdles in obtaining approval for such products. Companies like Collegium Pharmaceutical and Egalet Corporation have also faced similar challenges in this space. The focus on pharmacokinetic data and the need for additional studies to support safety claims are common themes in the development of abuse-deterrent opioids.

Comparison to Industry Standards

• Purdue Pharma's OxyContin reformulation set a precedent for abuse-deterrent opioid technology, but it also faced scrutiny regarding its effectiveness in preventing abuse.
• Companies like Teva Pharmaceutical Industries and Mylan (now Viatris) have developed generic versions of abuse-deterrent opioids, demonstrating the competitive landscape.
• The FDA's guidance on abuse-deterrent opioids outlines the types of studies required for approval, including in vitro manipulation and extraction studies, pharmacokinetic studies, and clinical abuse potential studies.
• Acura's approach with LIMITx technology, focusing on non-linear peak drug concentrations, is similar to other companies' efforts to reduce the risk of abuse through formulation technologies.

Stakeholder Impact

• Shareholders are impacted by the progress and potential risks associated with LTX-03 development.
• The development of LTX-03 could potentially impact patients seeking pain relief with abuse-deterrent properties.
• The company's employees are impacted by the ongoing development and regulatory processes.

Next Steps

• Conduct an additional human pharmacokinetic study (AP-LTX-310).
• Produce new clinical supplies of LTX-03.
• Evaluate whether to conduct a study to support the lower dosage strengths of LTX-03 (5/325mg and 7.5/325mg) either before or after NDA approval.
• Further deliberations and analyses by the Companies.

Key Dates

Keywords

LTX-03, Acura Pharmaceuticals, Abuse Deterrent Pharma, FDA, LIMITx technology, Hydrocodone, Acetaminophen, NDA, Pharmacokinetic study, Opioid, Pain relief